![Larry Norton, MD -- Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/458/image/norton-larry.jpg?h=10d202d3)
Larry Norton, MD
Breast Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Senior Vice President, Office of the President
- Medical Director, Evelyn H. Lauder Breast Center
- Norna S. Sarofim Chair in Clinical Oncology
I am a board-certified medical oncologist with broad interests in cancer prevention, diagnosis, and treatment. In my clinical practice I care for women with breast cancer, and I am Medical Director of the Evelyn H. Lauder Breast Center.
Read more
My research concerns the basic biology of cancer; the mathematics of tumor causation and growth; and the development of approaches to better diagnosis, prevention, and drug treatment of the disease. I am involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors, and vaccines. A major milestone in my research career was the development of an approach to therapy called “dose density,” or “sequential dose density.” This is a new and more effective way of using anticancer drugs, based on a mathematical model I developed with my colleagues, which maximizes the killing of cancer cells while minimizing toxicity.
I am currently the principal investigator of a program project grant from the National Cancer Institute (NCI) that is aimed at better understanding breast cancer in the laboratory and in bringing these advances into clinical practice.
On a national level, I was formerly the Chair of the Breast Committee of the NCI’s Cancer and Leukemia Group B. I was President of the American Society of Clinical Oncology (ASCO) from 2001 to 2002, and was appointed by President Clinton to serve on the National Cancer Advisory Board (the board of directors of the NCI).
Among many awards over the course of my career, I was honored to receive ASCO’s highest honor, the David A. Karnofsky Award, and was McGuire Lecturer at the San Antonio Breast Cancer Symposium. I am an author of more than 350 articles and many book chapters, have served as a visiting professor throughout the United States, Canada, South America, Europe, Israel, and Asia, and also have trained many cancer doctors and researchers.
A breast oncologist is a doctor with special training in breast cancer.
My Specialties
- Breast Cancer
Education
- MD, Columbia University
Residencies
- Internal Medicine - Bronx Municipal Hospital Center
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- Medical Oncology - National Cancer Institute
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Norton sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Karen Drucker. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Norton
- A Phase 1 Study of Pembrolizumab Immunotherapy and Cryoablation in People With Advanced Breast Cancer
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Norton’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Larry Norton discloses the following relationships and financial interests:
-
Agenus Inc.
Professional Services and Activities -
American Society of Clinical Oncology (ASCO)
Professional Services and Activities (Uncompensated) -
BlackRock, Inc.
Professional Services and Activities -
Breast Cancer Research Foundation
Professional Services and Activities (Uncompensated) -
Codagenix, Inc
Equity
-
Cold Spring Harbor Laboratory
Professional Services and Activities -
Cure Breast Cancer Foundation
Intellectual Property Rights; Professional Services and Activities (Uncompensated) -
Springer Nature Limited
Professional Services and Activities (Uncompensated) -
Translational Breast Cancer Research Consortium
Professional Services and Activities (Uncompensated) -
U.S. Department of Justice
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].